Anti-VEGFA antibody [11B5] (ab38909)
- Datasheet
- References (3)
- Protocols
Overview
-
Product name
Anti-VEGFA antibody [11B5]
See all VEGFA primary antibodies -
Description
Mouse monoclonal [11B5] to VEGFA -
Host species
Mouse -
Tested applications
Suitable for: WB, IHC-Fr, IHC-Pmore details -
Species reactivity
Reacts with: Mouse, Guinea pig, Human -
Immunogen
Synthetic peptide corresponding to Human VEGFA (N terminal).
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
Storage buffer
Preservative: 0.05% Sodium azide
Constituent: PBS -
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
11B5 -
Isotype
IgM -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
Our Abpromise guarantee covers the use of ab38909 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | 1/500. Predicted molecular weight: 24 kDa. | |
| IHC-Fr | 1/10. | |
| IHC-P | Use at an assay dependent dilution. |
Target
-
Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. -
Tissue specificity
Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. -
Involvement in disease
Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. -
Sequence similarities
Belongs to the PDGF/VEGF growth factor family. -
Cellular localization
Secreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. - Information by UniProt
-
Database links
- Entrez Gene: 7422 Human
- Entrez Gene: 22339 Mouse
- Omim: 192240 Human
- SwissProt: P15692 Human
- SwissProt: Q00731 Mouse
- Unigene: 73793 Human
- Unigene: 282184 Mouse
-
Alternative names
- Folliculostellate cell-derived growth factor antibody
- Glioma-derived endothelial cell mitogen antibody
- MGC70609 antibody
see all
References
This product has been referenced in:
- Liu XQ et al. lncRNA MALAT1 Accelerates Wound Healing of Diabetic Mice Transfused with Modified Autologous Blood via the HIF-1a Signaling Pathway. Mol Ther Nucleic Acids 17:504-515 (2019). Read more (PubMed: 31344658) »
- Tawfik A et al. Alterations of retinal vasculature in cystathionine-Beta-synthase mutant mice, a model of hyperhomocysteinemia. Invest Ophthalmol Vis Sci 54:939-49 (2013). Read more (PubMed: 23307965) »
